Reduction in CCP use may have resulted in 29,000 excess deaths in the U.S. from mid-November 2020 to February 2021
FDA Approves Third COVID-19 Antibody Treatment for Emergency Use
Study found that patients who received sotrovimab showed an 85 percent reduction in their risk for hospitalization or death versus placebo
Antibody Cocktail May Curb Infection in Unvaccinated Exposed to COVID-19
Drug company will ask FDA to expand the drug’s EUA to allow it to be given for preventive purposes in ‘appropriate populations’
COVID-19 Antibody Treatments Exceed Expectations in Early Trials
Eli Lilly and Regeneron asking regulators to expand authorization of their drugs based on the new findings
IgG Level in Convalescent Plasma Affects COVID-19 Death Risk
Risk for death reduced with higher versus lower levels of anti-SARS-CoV-2 IgG, but only in patients not receiving mechanical ventilation
Early High-Titer Plasma Reduces Progression of COVID-19
Early administration of high-titer convalescent plasma against SARS-CoV-2 reduces progression in mildly ill older adults
Red Cross Issues Call for More Blood Plasma to Treat COVID-19 Patients
People who have recovered from COVID-19 may have antibodies in their plasma that could boost immunity in current patients
COVID-19 Outcomes Not Improved With Convalescent Plasma
Clinical status, mortality did not differ for convalescent plasma versus placebo in adults with severe COVID-19 pneumonia
Nebulized Interferon Beta-1a Promising for COVID-19
Adults hospitalized for COVID-19 receiving SNG001 versus placebo more likely to show clinical improvement
Convalescent Plasma Has Limited Benefit for Moderate COVID-19
Randomized phase II trial shows no drop in progression to severe disease, all-cause deaths